LineaRx

No. 486: On mega-moons, linear DNA and innovative immigrant services – and yes, lots of coronavirus stuff

  The unusual: Welcome to Wednesday, dear readers, and the midpoint of another weird and wild workweek, as the Great Coronavirus Pandemic continues to reshape our world and the regional and global innovation economies scramble to keep up. Please celebrate alone: It’s March 25 out there, the U.N.’s International Day of Solidarity With Missing or Detained Staff Members, which is actually about U.N. employees who made the ultimate sacrifice, but seems oddly redefined today. To…


Island firm speeds coronavirus vaccines toward tests

By GREGORY ZELLER // Just weeks after announcing an expanded international collaboration targeting the menacing novel coronavirus, Applied DNA Sciences is preparing to mass-produce four potential vaccines. Leveraging the Stony Brook-based biotech’s unique DNA-manufacturing abilities, Rome, Italy-based Takis Biotech will test potential vaccines against the coronavirus (now going by COVID-19) in laboratory mice, on a large scale. Applied DNA expects delivery of four DNA-based “preclinical vaccine candidates” from Takis this month, and “within weeks” will…


No. 477: In which the Suffolk IDA incentivizes and the double helix debuts – plus, sticky buns for all!

  Just a word or two: Welcome to Friday, dear readers, as we wrap up another busy workweek and look forward to another well-earned weekend. It’s Feb. 21 out there, and before we begin, please speak up – today is International Mother Language Day, the U.N.’s multicultural salute to linguistic diversity. Going to extremes: Today is also National Grain-Free Day (a big one for the low-carb set) and National Sticky Buns Day (not so much)….


Applied DNA to speed up coronavirus countermeasures

By GREGORY ZELLER // Look out, coronavirus – Applied DNA is coming for you. Adding to its growing portfolio of cutting-edge Polymerase Chain Reaction-based projects, Stony Brook-based Applied DNA Sciences is expanding its Joint Development Agreement with Italian R&D company Takis Biotech, with the headline-making 2019-nCoV in their sights. Already hot on the trail of new cancer vaccines, the partners will now work on a “linear DNA” vaccine against the dreaded Wuhan, China-based illness that’s…


‘Linear DNA’ combo shows punch in cancer fight

By GREGORY ZELLER // Mark another impressive victory for LineaRX, this time in a two-front battle against cancer. The Stony Brook-based biotech with innovation in its DNA (literally) has lent its unique DNA-sequencing technology to two vaccine-candidate tests run by Italian R&D company Takis Biotech, which is hot on the trail of new therapeutic cancer vaccines. It might be catching up. On Thursday, LineaRX announced that both vaccines – each produced in “linear DNA” form…


For Applied DNA, new blood – and a shot in the arm

By GREGORY ZELLER // Just 11 months after spinning off from its parent company, a Stony Brook startup with expansion in its DNA has made its first corporate acquisition. LineaRX, a subsidiary of Applied DNA Sciences, has acquired the physical assets and intellectual property of Vitatex Inc., a private biotech with close ties to Stony Brook University and a patented method of isolating Invasive Circulating Tumor Cells in standard blood samples – spotting metastatic cells…


No. 349: Canada’s new high, Sikes’ new heights and LineaRX’s highest hopes (plus, repainting President Trump)

  Middle ground: Welcome to Wednesday, dear readers, and the halfway point of another exciting week of socioeconomic innovation. October 17 is in full swing, marking the 25th anniversary of the International Day for the Eradication of Poverty, a U.N. General Assembly effort to address shortages of basic necessities (i.e.: food, clothing, shelter) around the globe and reinforce the notion that poverty and human-rights abuses routinely coexist. Learn more here. Eye of the beholder: On…


At LineaRX, putting the horsepower behind the CAR T

By GREGORY ZELLER // Marking a big step in the war against cancer, a Stony Brook-based startup has initiated pre-clinical development of a non-viral, plasmid-free chimeric antigen receptor modified T-cell manufacturing platform. In English: A novel platform designed to develop and manufacture new pharmaceutical treatments, including treatments for different forms of cancer. The tech comes from LineaRx Inc., a wholly owned subsidiary that officially spun off from Stony Brook-based Applied DNA Sciences in September. Noting…


With new spinoff, biotech goes all-in on DNA sales

By GREGORY ZELLER // A Stony Brook biotech with a growing international reputation for supply-chain security has spun off a new company focused on DNA modification and production. Stony Brook-based Applied DNA Sciences on Tuesday announced the formation of LineaRx Inc., a wholly owned subsidiary that will concentrate on commercializing the parent company’s extensive experience in the design, manufacture and chemical modification of DNA by large-scale polymerase chain reaction – big news for scientists working…